Skip to content

Effects of transcutaneous auricular stimulation on pupil response in older adults and people with Parkinson's disease

Effects of transcutaneous auricular stimulation on pupil response in older adults and people with Parkinson's disease - NORA

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00037865
Enrollment
30
Registered
2025-09-30
Start date
2025-10-03
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Individuals with Parkinson's disease, group of healthy older individuals

Interventions

Group 1: Transcutaneous auricular vagus nerve stimulation (taVNS), true stimulation (3 seconds of stimulation and 12 seconds of pause over a total duration of 10 minutes during pupil measurement) in b

Sponsors

Universitätsklinik für Neurologie, Evangelisches Krankenhaus Oldenburg
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: - German as native language or adequate German language skills - Adults (= 18) - Normal cognitive screening (MoCA test > 21 points)

Exclusion criteria

Exclusion criteria: - Previous neurological or psychiatric conditions (except Parkinson's disease) - Relevant eye conditions (including previous eye surgery, glaucoma, pseudoexfoliation syndrome at the edge of the pupil or on the lens, corneal disease, nonspherical pupils, relevant anisocoria), diabetes mellitus - Use of centrally acting medications (except for Parkinson's medication) - Multifocal contact lenses, reflective glasses, or glasses with lots of shiny decorations (if these can be taken off/removed and the visual acuity is sufficient to be able to fixate on the fixation cross, the test subjects can be included and the measurement will take place without the visual aid)

Design outcomes

Primary

MeasureTime frame
Difference between pupil dilation before (baseline) and after taVNS (or sham stimulation)

Secondary

MeasureTime frame
- Reaction time during cognitive tasks (TAP-M) - REM sleep disorder (IRBD-SSS-PT)

Countries

Germany

Contacts

Public ContactKarsten Witt

Universitätsklinik für Neurologie, Evangelisches Krankenhaus Oldenburg

karsten.witt@uni-oldenburg.de+49(0)441 236 649

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026